Pharmacogenetics and pharmacogenomics in glaucoma therapeutics:the way to personalized therapy  

作　　者：Shiyu Liao Lixiang Wang Xin Wei 

机构地区：[1]Department of Ophthalmology,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China

出　　处：《Chinese Medical Journal》2023年第21期2573-2575,共3页中华医学杂志（英文版）

基　　金：supported by grants from the Natural Science Foundation of China(No.82070954);the Innovative Spark Grant of Sichuan University(No.2018SCUH0062);1·3·5 project for disciplines of excellence–Clinical Research Incubation Project,West China Hospital,Sichuan University(No.2021HXFH057);the“0-1’”Innovation Research Project of Sichuan University(No.2022SCUH0036).

摘　　要：Glaucoma is a leading cause of irreversible optic nerve damage,with a significant proportion of patients(approximately 10%)suffering from blindness or severe visual field damage during their lifetime.^([1])The number of patients suffering from glaucoma worldwide is estimated to be 76 million in 2020 and is expected to rise to 111.8 million by 2040.^([2])The estimated global prevalence of primary open-angle glaucoma(POAG)is 3.05%and primary angle-closure glaucoma is 0.50%in those aged 40 to 80 years,and the prevalence increases with age,^([2])which imposes a significant economic burden.Elevated intraocular pressure(IOP)is a well-recognized risk factor for glaucoma progression;although some natural products such as citicoline and coenzyme q10 have been shown to possess neuroprotective properties for delaying the progression of glaucoma,^([3,4])IOP-lowering medications are currently the mainstay in its medical management.

关 键 词：GLAUCOMA protective DAMAGE 

分 类 号：R775[医药卫生—眼科]